Three FDA-approved medications exist for treating opioid use disorder (OUD), each with distinct mechanisms and delivery options, though significant barriers continue to limit access despite strong evidence of their effectiveness.
Medication Options for OUD
Methadone, a full opioid agonist taken orally once daily, typically requires daily visits to an opioid treatment program. Buprenorphine, a partial agonist available in daily oral or weekly/monthly subcutaneous injection formulations, can block the binding of other opioids but risks precipitated withdrawal if initiated in patients with opioids in their system. Naltrexone, an opioid receptor antagonist available as a daily oral tablet or monthly intramuscular injection, requires 7 to 10 days of abstinence before initiation and carries no abuse potential. Methadone and buprenorphine are considered gold standard treatments, having demonstrated evidence for reducing death risk in patients with OUD and showing greater treatment retention compared to naltrexone. Combining medications with psychosocial treatment generally produces the best clinical results, though a patient’s decision to decline psychosocial treatment should not prevent or delay MOUD use, which alone has demonstrated efficacy.
Treatment Access Barriers
Stigma remains one of the most significant challenges, with substance use disorders often viewed as moral failings rather than brain diseases. An estimated 15% of the 1.8 million incarcerated individuals in the US have OUD, with related costs reaching $52 billion. Rural and underserved areas face acute provider shortages, with many US counties lacking even a single MOUD provider. Policy barriers included the X-waiver requirement for buprenorphine prescribing, eliminated in 2023, though buprenorphine prescribing and utilization have not increased as expected since then.
Criminal Justice Intersections
Individuals are at highest risk for overdose death immediately following release from correctional settings. A study found individuals had 129 times greater risk of overdose death compared to the general population following prison release. Despite evidence supporting medication-assisted treatment in criminal justice populations, only 44% of jails offered any MOUD form, and only 13% of jails with MOUD available actually offered it to anyone with OUD—representing a significant missed opportunity for implementing life-saving interventions.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.psychiatrictimes.com/view/combatting-the-opioid-crisis-with-evidence-based-treatments